DEC 04, 2014 12:00 AM PST

Researchers Use Evolutionary Tenets to Model Cancer Mutations: Spot potential therapeutic targets

WRITTEN BY: Judy O'Rourke
Cancer researchers aiming to gain new insights into the disease are looking at it from a new angle. Through the prism of evolutionary principles and computational modeling they are probing the role of particular genetic mutations in the Darwinian struggle among tumor and normal cells during cancer growth.

Healthy cells become malignant by amassing genetic mutations that lead to increased survival and reproduction. In contrast to prior research that regards cancer progression as the product of the unlimited build-up of these genetic mutations, researchers at the Moffitt Cancer Center, Tampa, Fla, are modeling cancer progression on the theory that cancer cells live in an environment that has finite resources (eg, space and nutrients) and is governed by evolutionary laws, which include a middle ground between multiplying and merely surviving.

The animal kingdom offers examples of either/or modes for longevity: aim for either a long lifespan or many babies. Elephants have few progeny and comparatively long lives, while rabbits have short lifespans and many babies. In their own way, cells that evolve to form cancers accomplish this by extending longevity or multiplying the number of offspring.

As with the big and small critters, cancer cell mutations can only travel down one evolutionary path at a time. So these cells can devote available resources in beefing up their defenses against attacks by normal tissue or tolerate a high mortality rate and prevail with extremely rapid proliferation-either/or.

Through computer simulations built on these concepts, the researchers determined that the frequency with which any genetic mutation is observed depends on its ability to increase the cell's fitness, its ability to survive, and reproduce-a process the researchers call "evolutionary triage."

"Genes that increase fitness are observed more frequently than those that do not," says Robert A. Gatenby, MD, chair of the Department of Diagnostic Imaging and co-director of the Cancer Biology and Evolution Program at Moffitt. "However, the effect of any mutation on cell fitness can change drastically depending on environmental factors such as blood flow, past genetic mutations, and the properties of competing cells. Currently, cancer biologists divide mutations into ‘drivers,' which promote tumor growth and ‘passengers,' which have no effect on growth. In the computer simulations, it was clear that many mutations could be drivers in one environment, but passengers in another."

Since driver mutations are common targets for cancer therapy, the scientists also simulated therapies that seek to disable driver genes. The researchers found that targeted therapies can destroy the mutated cells and shrink the tumor size, akin to results seen in clinical settings. But the range of tumor environments creates many mutational pathways to formation of a malignant cell. Cancer cells without the driver mutation that are resistant to therapy were almost always present and caused the tumor to reappear.

The researchers were surprised to find that some genes were never observed to be mutated in cancers. Mutations in these genes always scaled down the tumor cell's ability to survive or reproduce. When they did occur, evolutionary triage obliterated them due to survival of the fittest. "Our computer simulations demonstrate an unexpected result - genes that are never observed to be mutated might actually be the best targets for therapy. This is because up or down regulation of these genes unconditionally reduces cell fitness," Gatenby says.

With assistance from a bioinformatics expert from the Scripps Research Institute, La Jolla, Calif, 1,100 genes that are never mutated in human cancers were identified. The research group is now working to investigate the possibility of targeting "never" genes for therapy.
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
SEP 15, 2021
Cell & Molecular Biology
The Molecular 'Anchors' That Hold Cells in Place
SEP 15, 2021
The Molecular 'Anchors' That Hold Cells in Place
Cells in the body are held in place with a kind of molecular anchor, called focal adhesions, where cells are linked to c ...
OCT 25, 2021
Cancer
Could Pomegranates Play a Role in Cancer Prevention or Treatment?
OCT 25, 2021
Could Pomegranates Play a Role in Cancer Prevention or Treatment?
Pomegranate (Punica granatum L) is an ancient fruit grown primarily in western Asia and Mediterranean regions.  ...
OCT 24, 2021
Microbiology
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
OCT 24, 2021
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
Bacteria can be found almost everywhere, and they can serve many beneficial purposes. Scientists are now using bacterial ...
NOV 18, 2021
Immunology
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
NOV 18, 2021
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
Antibody therapies harness the immune system's power to fight a broad spectrum of diseases, from cancer to infectiou ...
NOV 25, 2021
Cancer
Could an Anti-Cancer Drug Treat Diabetes?
NOV 25, 2021
Could an Anti-Cancer Drug Treat Diabetes?
Diabetes and cancer are two common diseases that share many similar risk factors. People with diabetes are also at& ...
DEC 23, 2021
Cancer
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
DEC 23, 2021
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
It is estimated that nearly 84,000 people will be diagnosed with bladder cancer in the United States this year ...
Loading Comments...